These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 22172854)

  • 1. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
    Niederau C; Mauss S; Böker K; Lutz T; Heyne R; Moog G; John C; Witthöft T; Alshuth U; Hüppe D
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and extended therapy for recurrent hepatitis C after liver transplantation.
    García-Pajares F; Almohalla C; Lorenzo Pelayo S; Ruiz Zorrilla R; Pinto P; Ramos C; Sanchez Antolin G; Paton AC
    Transplant Proc; 2012; 44(6):1571-3. PubMed ID: 22841217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
    Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S; Abdel-Ghaffar TY; El-Karaksy H; Abdel-Aty EF; El-Raziky MS; Allam AA; Helmy H; El-Araby HA; Behairy BE; El-Guindi MA; El-Sebaie H; Abdel-Ghaffar AY; Ehsan NA; El-Hennawy AM; Sira MM
    World J Gastroenterol; 2014 Apr; 20(16):4681-91. PubMed ID: 24782620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
    Calmus Y; Duvoux C; Pageaux G; Wolf P; Rostaing L; Vanlemmens C; Botta-Fridlund D; Dharancy S; Gugenheim J; Durand F; Néau-Cransac M; Boillot O; Chazouillères O; Samelson L; Boudjema K; Samuel D
    J Hepatol; 2012 Sep; 57(3):564-71. PubMed ID: 22613001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C.
    Yedibela S; Demir R; Melling N; Aydin Ü; Schuppan D; Müller V; Hohenberger W; Schönleben F
    Clin Transplant; 2011; 25(1):131-5. PubMed ID: 20438578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection.
    Singhal A; Jain AB; Burke M; Black M
    Exp Clin Transplant; 2010 Sep; 8(3):214-9. PubMed ID: 20716039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
    Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
    Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
    Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
    Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.